← Back to patent-cliff list
ENERGI-F703
Tier C — Watch / tradeENERGI-F703
Energenesis Biomedical Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AMPK
Indications (approved)：Trauma and injury, Diabetes, 糖尿病足溃疡, 足溃疡, 静脉曲张溃疡
Regional status
US
Phase III
2023-05-30
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ENERGI-F703?
Approved indications include: Trauma and injury, Diabetes, 糖尿病足溃疡, 足溃疡, 静脉曲张溃疡.
When does the ENERGI-F703 patent expire?
No public expiry year is available for ENERGI-F703 yet; this page updates once verified.
How do I get a quote for ENERGI-F703 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03